Trade Ideas November 17, 2026 03:47 AM

United States Antimony: Volume Spike, Price Reset — A Tactical Buy for a Mid-Term Bounce

Shares weakened after disappointing Q3 and heavy selling; fundamentals are messy but the risk/reward favors a disciplined long trade into improving volumes and defense orders.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
UAMY

United States Antimony (UAMY) has seen heavy intraday selling that dropped the stock to $2.67 on elevated volume while average volume remains high. Fundamentals remain challenged - negative earnings, negative free cash flow, and a recent revenue miss - but the company sits as a domestic critical-minerals supplier with large government orders and improving trading technicals. We view this as a tactical long (swing) with a tight stop and a mid-term target that captures mean-reversion into structural catalysts.

United States Antimony: Volume Spike, Price Reset — A Tactical Buy for a Mid-Term Bounce
UAMY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Entry at $2.67 with stop at $2.45 and target $4.00 — mid-term swing (45 trading days).
  • Market cap ~$398.7M; EV ~$368.9M; price-to-sales ~10.5 despite negative free cash flow (-$68.3M).
  • Q3 revenue $10.13M and EPS -$0.06; recent delivery cadence and government orders are the primary fundamental catalysts.
  • Technicals: elevated volume, RSI ~40 and MACD histogram turning slightly positive suggest room for mean-reversion.

Hook & thesis

United States Antimony (UAMY) has just gone through a painful price reset: shares fell to $2.67 on 11/16/2026 after a week of weak headlines and a revenue miss, yet trading volume remains elevated — today’s volume was roughly 6.05M vs. a two-week average near 6.06M. That combination - outsized liquidity with a clear break in price - can produce a sharp rebound when headline pressure eases and flows stabilize.

We recommend a tactical long - not a buy-and-forget position - sized as a swing trade over the next 45 trading days. Entry at $2.67 with a disciplined stop at $2.45 limits downside to roughly 8% while setting a target of $4.00 captures the likely mean-reversion toward the mid-term moving averages and a technical recovery. The trade is high-risk but offers attractive asymmetry: reward-to-risk here is near 6:1 if the company can steady volumes and benefit from pending defense-related demand.

What the company does and why the market should care

United States Antimony extracts and processes antimony, zeolite, and precious metals through four operating segments: U.S. Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and U.S. Zeolite Operations. The company occupies a unique position as one of the only major domestic antimony processors - a critical mineral for flame retardants, lead-acid batteries, and defense applications.

Market relevance here is two-fold. First, antimony is designated a critical mineral in the context of supply security; U.S. government demand and funding for near-shoring projects are a structural tailwind. Second, the stock is heavily traded and levered to short-term flows: short interest has been material (recent settlement ~38.7M shares with days-to-cover roughly six days), which amplifies volatility and creates the potential for sharp intraday moves when buyers return.

Key recent numbers

  • Share price: $2.67 (current)
  • Market cap: ~$398.7M
  • Shares outstanding: ~149.33M; float ~135.30M
  • 52-week range: $2.53 - $12.64 (low on 11/05/2026, high on 05/06/2026)
  • Q3 results (reported 11/12/2026): loss of $0.06 per share; revenue $10.13M (missed estimates by ~40.6%)
  • Operating cash flow: negative $20.7M for the first half of 2026 (management commentary)
  • Balance sheet / liquidity: current ratio 4.66, quick ratio 2.83; cash figure flagged at $1.96 (per reported ratio item)
  • Profitability & valuation metrics: EPS -$0.14 (TTM), price-to-sales ~10.53, EV-to-sales ~9.74, free cash flow -$68.29M

How this supports the trade

The immediate bullish case is technical and flow-driven. The stock is near its 52-week low ($2.53) after a 2026 pullback; the 10- and 21-day EMAs sit above current price (EMA9 ~ $2.97, EMA21 ~ $3.11), and RSI is below neutral (~40), leaving room for a bounce. MACD shows a small bullish histogram, suggesting short-term bullish momentum may be forming.

Fundamentally, UAMY remains a play on domestic critical-mineral supply and defense demand. Management completed DLA shipments and highlighted contractual orders in the tens of millions; the company reported completion of initial shipments (82,000 pounds generating ~$2.6M) and cited order flow of ~$57.3M across defense programs earlier in the year. If delivery cadence and antimony prices stabilize, revenue and cash flow trajectories could improve materially versus the lows, which would justify a re-rating from current depressed multiples.

Valuation framing

At a market cap near $398.7M and an enterprise value around $368.9M, UAMY is trading at elevated revenue multiples (price-to-sales ~10.5, EV-to-sales ~9.7) despite being unprofitable and negative on free cash flow (-$68.3M). Those multiples reflect scarce domestic supply and optionality tied to defense contracts, but they also embed higher expectations relative to current revenue run-rate. In short: the equity is priced for a narrative (securing long-term, higher-margin government business) rather than current earnings power.

That makes this a trade, not a fundamental value buy. A successful rebound requires improvement in sales cadence and working capital outcomes; absent that, the valuation premium is unjustified and downside risk remains.

Catalysts to watch (2-5)

  • Government contract deliveries and timing - confirmation of follow-on shipments under DLA and Defense Logistics support will reduce uncertainty and prove order realization.
  • Quarterly operational updates - sequential revenue improvement and better-than-feared delivery timing would be an immediate positive.
  • Antimony price direction and China export policy - improving prices or renewed export curbs overseas would support margins.
  • Any management action on capital allocation - a shift from buybacks to working capital or targeted capex could reassure markets after summer criticism over buybacks.

Trade plan (actionable)

We recommend a long trade with the following rules:

  • Entry: buy at $2.67.
  • Stop loss: $2.45. This sits below the nearby 52-week low ($2.53) and limits the downside to ~8% from entry.
  • Target: $4.00. This is our mid-term technical target (about 50% upside) and sits above the 50-day moving average (~$3.72), allowing for a pullback/rotation back toward prior short-term support/resistance levels.
  • Horizon: mid term (45 trading days). Expect the trade to play out over several weeks as order confirmations, shipment cadence, and short-covering dynamics unfold; do not treat this as an overnight scalp.

Position sizing: keep exposure modest given the company’s negative free cash flow and revenue misses. Consider taking profits incrementally at $3.50 and $4.00, and tighten stops if the stock breaks above $3.50 on strong volume to protect gains.

Risks & counterarguments

This trade is far from risk-free. Key risks include:

  • Execution risk: The company has reported sequential revenue misses (Q3 revenue $10.13M missed consensus and Q2 sales were weak). Continued delivery timing issues or missed shipments would sink sentiment and revenue.
  • Cash-flow & capital allocation: Operating cash flow was negative in early 2026 and free cash flow is deeply negative. Management previously authorized buybacks which drew criticism while liquidity remains constrained; further cash burn could force equity raises or scaled-back operations.
  • Commodity-price and market risk: Antimony prices are volatile and tied to global supply/demand and Chinese policy. A renewed price slump or easing of export constraints overseas would reduce margin potential.
  • High short interest and volatility: Elevated short interest means the stock can move violently in either direction; while that creates upside on short-covering, it also amplifies downside during negative news.
  • Valuation disconnect: Current multiples assume a narrative recovery. If the company cannot convert orders into profitable cash flow, the market could re-rate the stock substantially lower.

Counterargument: Critics will point to the revenue misses, negative cash flow, and the company’s relatively high price-to-sales multiple as signs that UAMY is structurally overvalued. That is a valid view: without material improvements to cash generation or a firming of antimony prices, the stock can re-test and breach the 52-week low. This trade only works if supply/demand and delivery trajectories begin to normalize within the next several weeks.

Conclusion - stance and what would change my mind

Stance: Buy (swing). The ideal trade capitalizes on heavy volume-driven price weakness and a clear support area near the 52-week low. Entry at $2.67 with a $2.45 stop and a $4.00 target offers a compelling risk/reward for a 45-trading-day trade given the company’s unique position in domestic antimony supply and real, if uneven, government order flow.

What would change my mind: sustained revenue deterioration, further negative guidance, or new evidence that government orders will be delayed materially would invalidate the thesis. Conversely, a confirmed pick-up in shipments, better-than-expected quarterly results, or positive developments on antimony pricing would strengthen conviction and shift this from a tactical swing to a longer-term position.

Key metrics table

Metric Value
Current price $2.67
Market cap $398.7M
EV $368.9M
Price-to-sales ~10.53
Free cash flow (trailing) -$68.3M
52-week range $2.53 - $12.64

Final note

This is a disciplined, tactical trade that relies on mean-reversion and update-driven execution. Size positions conservatively, set the stop at $2.45, and reassess if the company fails to show shipment execution or if cash-burn accelerates materially. If catalysts line up, the trade should reach the mid-term target within 45 trading days; if not, accept the stop and move on.

Risks

  • Execution risk: continued delivery timing issues or missed shipments would push revenue lower and crush sentiment.
  • Cash-flow & capital risk: negative operating cash flow and large negative free cash flow could force dilutive financing.
  • Commodity & policy risk: antimony prices and Chinese export policy can swing margins sharply against the company.
  • Volatility and short-squeeze risk: elevated short interest can amplify sell-offs as well as rallies; rapid reversals are common.

More from Trade Ideas

Forestar Group: Cheap Land, Strong Cash Flow — A Tactical Long Nov 17, 2026 CoreWeave Is Mispriced: High Debt Yield vs. Low Cost of Debt Creates an Asymmetric Long Nov 17, 2026 Deckers (DECK) - A Cautious Swing Buy on International Strength Nov 17, 2026 Kura Oncology: Komzifti Refill Momentum Offers a Tradeable Upside—Funding Update Will Set the Next Leg Nov 17, 2026 Buy LyondellBasell on Cash Flow and Yield — Short-Term Noise, Long-Term Optionality Nov 17, 2026